QTVascular

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

FOR IMMEDIATE RELEASE

QT Vascular's Products Receive Positive Feedback at World's Largest Interventional Cardiovascular Conference

- TCT (Transcatheter Cardiovascular Therapeutics) is the world's largest educational meeting specializing in interventional cardiovascular medicine
- Recognition of unique potential of products by eminent group of world-renowned physicians is expected to further increase awareness among physicians
- Growth strategy of rapidly and concurrently advancing pipeline products via both organic (in-house) and inorganic (licensing and acquisition) efforts

Singapore, 23 September 2014 – Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that it has concluded a successful presence at the TCT conference in Washington DC, that included several scientific presentations and the use of one of its products during a live case transmission.

Specifically, these presentations and live-case transmissions included the following:

- In a live satellite transmission from Riverside Methodist Hospital in Columbus Ohio, to the convention center in Washington DC, Dr. Gary Ansel used a 3.0x80mm Chocolate® PTA to treat a patient suffering from severely stenosed popliteal artery. Due to its location behind the knee which is subject to extreme bending and compression, the popliteal artery is sometimes considered a "no-stent" zone.
- TriReme's Chocolate® PTA technology was prominently featured in several presentations at the "New Paradigms for Coronary and Peripheral Interventions Symposium" on September 14th 2014:
    - In a presentation titled "Introduction: Beyond Balloons and Stents", Dr. Martin Leon, Professor of Medicine at Columbia University Medical Center described the history of interventional tools from balloons to stents. Despite the progress made in reducing restenosis by the use of drug-eluting stents, concerns are mounting due to the increasing cumulative incidence of late thrombosis. This has opened the door for treatment platforms that do not leave behind a permanent implant.
    - Dr. Jihad Mustapha, Director of Endovascular lab and Cardiovascular research at Metro hospital in Grand Rapids Michigan, presented updated interim results of the Chocolate BAR registry. The Chocolate® BAR registry has now enrolled a total of over 480 patients (one of the largest peripheral registries), including over 220 patients in the highly complex below-the-knee (BTK) cohort. Remarkably, only 2% of the patients in this challenging cohort required a bail out stent and at 3 months, the rate of amputation-free survival was a high 98%, while the rate of re-intervention was only 5%.
    - Dr. Mehdi Shishehbor, Director of Endovascular Services at the Cleveland Clinic discussed the limitations of current endovascular treatment options, the shift away from the use of permanent implants, and the role that Chocolate® PTA plays in his treatment of high risk

patients such as those with critical limb ischemia. He closed by announcing the trial structure of ENDURE, a clinical trial of the Group's drug coated balloon, Chocolate® Touch.

- In a presentation titled "Chocolate® PTCA – A New Treatment Paradigm and Case Review", Dr. Bruno Scheller of University of Saarland, Germany, described the initial experience in using the Chocolate® PTCA (heart version) as a vessel preparation device prior to the use of a drug-coated balloon or a drug-eluting stent in coronary de novo lesions. In this early experience with the device, coronary stents were used in less than 60% of lesions (compared to over 90% in everyday practice for his heart patients).
- Dr. David Rizik, Director of the Heart and Vascular Division of the Scottsdale (AZ) Heart Group presented the results of the Glider PTCA EU registry, showed several successful case studies demonstrating Glider's specialty characteristics in treating lesions that are difficult and sometimes impossible to treat with conventional balloons, and announced the plans for a clinical registry of Glider use in the United States.

Dr. Eitan Konstantino, the Group's Chief Executive Officer, commented, ***"It is an honour that such an eminent group of world-renowned physicians has recognized the unique potential of our peripheral and coronary products. We will continue to invest in development of cutting edge technologies and will also look to license and or acquire unique products that offer improved treatment options for patients and could expand our line of specialty balloons and catheters."***

- End –

About Coronary Artery Disease

Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.

About Peripheral Artery Disease

Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide.

About QT Vascular Ltd.

QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

For more information, please refer to: http://www.qtvascular.com/

References:

(1) *Das T for Mustapha J. Chocolate® Bar, Leipzig Interventional Course, 28-31 January, 2014.*
(2) *"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.*

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd
Kamal SAMUEL, kamal@financialpr.com.sg
Mark LIN, marklin@financialpr.com.sg
Tel: (65) 6438 2990 Fax: (65) 6438 0064

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.